This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The study was a nonrandomised trial with concurrent controls and was carried out in patients' homes in two health regions. The loss to follow up was 4.76% (3 patients), all of whom were from Cambridgeshire.
Analysis of effectiveness
The analysis of the clinical study was based on treatment completers only. The health outcome measures consisted of: physiological indicators (such as forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEF), and the resting oxygen saturation breathing air (SaO2); patient satisfaction, obtrusiveness, and ease of use of the oxygen system assessed by a series of visual analogue scale (VAS) questions; and quality of life with regard to fatigue, emotional function and mastery evaluated by the VAS adjusted chronic respiratory disease questionnaire. The health outcome measures were reported for each limb of the study and each region. The groups were shown to be comparable in terms of physiological indicators at the beginning of the study.
Effectiveness results
The study revealed no significant differences between the groups and during the two limbs of the study in terms of physiological indicators. The study revealed that patients using concentrators had significantly (P<0.05) higher scores in terms of VAS and quality of life indicators (patient satisfaction, obtrusiveness, ease of use, fatigue, emotional function and mastery) compared with patients using cylinders, except in terms of "mastery" in the Suffolk group (P= 0.12) (the exact values of the results regarding VAS and quality of life indicators were not reported).
Clinical conclusions
The study revealed that the patients with less than 8 hours per day of use of oxygen "found the oxygen concentrator a more useful and acceptable means of oxygen delivery, and the VAS results also suggest that this may be associated with improvements in several dimensions of quality of life".
Measure of benefits used in the economic analysis
No summary benefit measure was identified in the economic analysis.
Direct costs
The assumptions made regarding the resources used were reported separately from the costs. The cost components were not reported separately. The minimum theoretical and actual costs of the cylinder supply per month were reported. The data related to actual cost of cylinders were supplied by the prescription pricing authority. The average cost of oxygen concentrators in the UK provided by a regional contractor was reported. The cost crossover point was identified. Only health services costs were considered. 1993 price data were used.
